Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
Can Sanofi buy its way into in vivo CAR-T?
Background, Latest NewsRecent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
Bionyra launches with $165m, France’s largest biotech Series A
Latest NewsWith an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
BioArctic signs potential $1bn Alzheimers research deal with Eli Lilly
Latest NewsBioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.
Theranostics as potential novel therapeutic pillar in oncology
Sponsored PublicationsSee-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
Novo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discovery
Latest NewsThe Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation push it set in motion earlier this year through a DKK5.5bn (€736 million) commitment to the BioInnovation Institute (BII).
Jazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCellera
Latest NewsDublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and political activist Peter Thiel.
F2G’s oral antifungal clears Phase III hurdle
Latest NewsUK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.
FDA opens path for uniQure’s Huntington’s gene therapy filing
Latest NewsAfter months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130.
AI: Breaking barriers in CNS research
BackgroundDelivering therapeutic genetic material safely to the correct target in the body is one of the big challenges of modern medicine. We talked to David Del Bourgo, CEO of WhiteLab Genomics, about how AI is helping design a new generation of vectors to tackle neurological diseases.
Europe’s imperative: Early-stage investors and company creation
OpinionEuropean biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.